New FTC Rule Means More Exclusive Patent Rights Transfers Must Be Reported

by Goodwin

Under a new rule that becomes effective on December 16, 2013, the Federal Trade Commission (“FTC”) has expanded the reach of the Hart-Scott-Rodino (“HSR”) Act to capture the transfer of a patent license even where the licensor retains manufacturing and other co-rights.  The new rule is initially limited to the transfer of licenses in the pharmaceutical industry.  The FTC, however, has stated that it will continue to consider the applicability of the new rule to other industries and advises that parties who are transferring rights to a patent or part of a patent should consult with the FTC to determine whether they may need to file notification under the HSR Act.

The HSR Act

The HSR Act requires transactions that meet certain thresholds in terms of value and the size of the parties be reported to the FTC and Department of Justice Antitrust Division before the parties can close.[1]  The HSR Act covers acquisitions of assets, in addition to acquisitions of voting securities and noncorporate interests such as partnership shares or limited liability company membership interests.

The Old Rule Covering Patent Rights

The FTC has for decades viewed an exclusive patent license to be the transfer of an asset that may require notification under the HSR Act.  The FTC has also historically taken the view that an exclusive license to use only part of a patent (such as a limited exclusive license to use the patent for certain therapeutic indications) or to use the patent in limited geographic territories was an asset acquisition that could require notification.  To determine whether a patent license was exclusive, the FTC adopted a test that asked whether the licensee would acquire the right to “make, use and sell” products under the patent or part of the patent to the exclusion of all others, including the licensor.  Under this analysis, the retention by the licensor of the right to manufacture product under the patent, even if it was for the exclusive use of the licensee (as is often the case in the pharmaceutical industry), rendered the patent non-exclusive and therefore not reportable under the HSR Act.

The new FTC rule does away with the “make, use and sell” test.  Now, the retention by the patent holder of limited manufacturing rights (even if it is solely for the use of the licensee) or other co-rights under a patent will not be sufficient to obviate the need for an HSR Act filing.

The New Rule Covering Patent Rights

Under the new rule that will be effective on December 16, 2013, the FTC will look to whether “all commercially significant rights” to a patent or part of a patent are being transferred.  The rule is not confined to patent licenses.  Instead, the transfer of rights under a patent – whether pursuant to an exclusive license or another form of transfer – may be reportable under the HSR Act even if the patent holder retains limited manufacturing rights or other co-rights, such as rights to co-develop, co-promote, co-market and co-commercialize.

The key to reportability will be whether the recipient obtains the exclusive right to use the patent as a whole, or a part of the patent in a particular therapeutic area or specific indication within a therapeutic area, to generate revenue (even if part of this revenue must be shared under the terms of the agreement with the patent holder).  The transfer of a subset of rights under a patent may be reportable if only the recipient can generate revenue from those exclusive rights.

The New Rule is Limited to the Pharmaceutical Industry

The FTC has limited the applicability of the new rule governing the transfer of exclusive patent rights to the pharmaceutical industry.  As the FTC explained when it implemented the new rule, it believes “the pharmaceutical industry is the only industry in which parties regularly enter into exclusive patent licenses that transfer all commercially significant rights.”  Somewhat opaquely, the FTC also explained in its announcement of the new rule that “transfers of exclusive rights to patents in other industries remain potentially reportable under the Act and existing HSR rules.”  In its announcement, the FTC twice recommended that parties who are contemplating exclusive license transfers outside the pharmaceutical industry consult with the FTC Premerger Notification Office for advice concerning their potential reporting obligations under the HSR Act.

Until it becomes clear how the FTC intends to apply the new rule, it will be good practice for any party who is negotiating a transfer of exclusive patent rights – whether in the pharmaceutical industry or other areas – to consult with HSR Act counsel regarding their transaction.  Parties to a transaction that must be notified under the HSR Act are required to observe certain waiting periods between filing and closing.  Parties who fail to make a required notification filing can be fined up to $16,000 per day.

[1] Currently, the basic thresholds that can trigger a filing under the HSR Act are (i) the value of the transaction must exceed $70.9 million, and (ii) one party to the transaction must have annual net sales or total assets of $141.8 million or more, and another party to the transaction must have annual net sales or total assets of $14.2 million or more.  At the beginning of each year, FTC adjusts these thresholds based on the change in gross national product from the prior year.

IRS Circular 230 Disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. tax advice contained in this informational piece (including any attachments) is not intended or written to be used, and may not be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.